Cimzia (also known by its generic name certolizumab pegol) is a biologic medication approved in September 2013 by the FDA for the treatment of active psoriatic arthritis and in May 2018 for the treatment of moderate-to-severe psoriasis in adults. It is also approved for treating rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
Cimzia is given by injection under the skin. For patients with psoriatic arthritis, Cimzia is given at week 0 (the first week of treatment) and week 4, and then every every other week afterwards. maintenance dosing every 4 weeks can be considered. For patients with psoriasis, Cimzia is given at week 0 and then every other week. For some patients with psoriasis, a dose at weeks 0, 2, and 4, followed by every other week may be considered.
To learn more, please visit the Cimzia website.
